| Literature DB >> 19636920 |
Navratna Vajpai1, André Strauss, Gabriele Fendrich, Sandra W Cowan-Jacob, Paul W Manley, Wolfgang Jahnke, Stephan Grzesiek.
Abstract
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19636920 DOI: 10.1007/s12104-008-9079-7
Source DB: PubMed Journal: Biomol NMR Assign ISSN: 1874-270X Impact factor: 0.746